Curis Inc (CRIS)

[cash2go]

Biased, but a link well worth reading

Curis and the Swiss Army Knife

12/7/2010

Rick Currin

On the failures:
* One has to wonder why Genentech chose two of the harshest trials for the drug."

* From our review of the research, several much more promising areas for hedgehog inhibition are small cell lung cancer, prostate cancer, pancreatic cancer, and breast cancer.

* So while hedgehog signaling may not have been effective in colorectal cancer or ovarian cancer harboring kras mutations it is feasible and perhaps even likely that adding a drug that helps block kras (a PI3K or HDAC inhibitor for example) will be effective in a combination. From our point of view Curis stands in a unique position to tackle combination therapies and attract licensees on its way to long term success

http://www.currinbiotech.com/articles/20101209